Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced that its Board of Directors has decided to explore potential strategic alternatives to enhance stakeholder value. The Company is engaging Moelis & Company, LLC as its financial advisor and Cooley, LLP as its legal advisor.
Read the full article: Senseonics Exploring Strategic Options to Enhance Stakeholder Value //
Source: https://www.businesswire.com/news/home/20200323005337/en/Senseonics-Exploring-Strategic-Options-Enhance-Stakeholder